drugset / Trial / NCT06379399
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF wild-type metastatic colorectal cancer.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-03
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | — |
| Subject | Trifluridine/Tipiracil | Unknown | 30 mg/m2 | Oral |
| Subject | Trifluridine/Tipiracil | Unknown | 35 mg/m2 | Oral |